生物医药数字化创新论坛通知

会议背景：
医药及生物科技领域近年来蓬勃发展，国际化程度日渐提高。该领域的私募融资交易数量不断攀升，2020 年度，其总融资金额超过 107 亿美元，单笔融资规模约 4400 万美元，同比增长 42%。我国 2020 年生物医药领域 IPO 融资总金额超 147 亿美元，其中以肿瘤等领域创新药公司投融资数额较大。由此所涉及的国际化战略、投融资与并购布局策略、尽职调查、知识产权保护等问题逐渐成为焦点走入各界视野。
 
Background：
The fields of medicine and biotechnology have developed vigorously in
 recent  years, and the degree of internationalization is increasing day
by day. The number of private financing transactions in this field continues to rise. In 2020, the total financing amount exceeded US $10.7 billion, and the single financing scale was about US $44 million, a year-on-year increase of 42%.
China's total IPO Financing in the field of biopharmacy in 2020. The amount exceeds US $14.7 billion, of which the investment and financing amount of innovative drug companies in tumor and other fields is large. Therefore, the internationalization strategy, investment and financing,
M & A layout strategy, due diligence, intellectual property protection and other issues involved have gradually become the focus and come into the vision of all walks of life.
 
会议日期：2021年12月8号
会议地点：上海浦东嘉里大酒店F1，浦东新区花木路1388号
会议规模：60-70人
 
13:00-13:10 推介会欢迎辞  Opening Remarks
Intralinks
13:10-13:40 主题报告--浪潮之下：中国生物医药的创新现状与未来风向
Session 1--Under the tide: innovation status and future direction of
biomedicine in China
徐佳熹 兴业证券董事总经理，研究院副院长，医药行业首席分析师
Dr.Jiaxi XU,Managing Director,Industrial Securities Co.,Ltd.
13:40-14:10 中国生物医药产业合作与投融资报告发布
Session 2 -- China's biomedical industry cooperation and investment
and financing report
中国医药工业信息中心
14:10-14:40 主题报告—“生物医药在中国”
-推动医药研发创新和准入方面的全球化发展
-中国如何成功地将本土制药能力从制造技术拓展到研发创新，并拥有更多的海外授权项目
Session 3 -- Pharma in China
- Driving global progress in innovation and access
-How successfully is China expanding its pharma capabilities beyond
manufacturing into innovation and having more license-out projects？
臧敬五博士，创始人、董事长，天境生物
Dr.Jingwu ZANG,Founder and Chairman,I-Mab Biopharma
14:40-15:00 茶歇  Coffee Break
15:00-15:30 主题报告--审而慎之：尽职调查在企业 IPO 以及并购等方向实践问题
Session 4-- Practice of due diligence in corporate IPO and M & A
叶玉盛，合伙人，竞天公诚律师事务所
Yusheng YE,Partner,Jingtian & Gongcheng LLP
15:30-16:00 主题报告—“合作研发”--一种强有力的关系组合，对未来的医药研发至关重要
Session 5 -- How Collaboration-A Powerful Relationship Combination Are Essential to the Future of Pharmacy R&D
张连山 博士，全球研发总裁，江苏恒瑞医药股份有限公司
Dr.Lianshan ZHANG,President of Global R&D，Hengrui Pharmaceuticals
16:00-16:30 主题报告：从投资和融资的角度来看，生物制药市场是否仍将“炙手可热”？
Session 6 -- Will the biopharma market remain “hot” from an investment and funding perspective?
尹正，三一创新，创始合伙人
Dr. Jack YIN,Partner,TIF
16:30-17:00 License out的趋势和策略
Trend and strategy of License out
富天，昂阔医药首席商务官、联合创始人，昂阔医药
Andy Fu, PharmD, MBA,Co-Founder, Chief Business Officer,OnCusp Therapeutics 
17:00-17:45 圆桌讨论—策略谈：2021 中国生物医药与健康创新投融资焦点
Panel：2021 Investment and financing of biomedicine and health innovation in China Purchase focus
- 2021 上半年中国生物医药及健康领域并购活动及各市场 IPO 情况说明
2021 Description of M & A activities in the field of biomedicine and health in China and IPO in various markets in the first half of the year
- 疫情常态化与监管政策中的投融资变化与未来分析
Investment and financing changes and future analysis in epidemic
normalization and regulatory policies  
- 中国正在如何逐步融入国际医药市场
How is China evolving in the international pharma market to access landscape
毛化，合伙人&董事总经理，弗若斯特沙利文咨询有限公司
袁宁，副首席商务官，复星医药
富天，昂阔医药首席商务官、联合创始人，昂阔医药
巫荟，董事总经理，泉创资本
李嘉，首席财务官，荣昌生物
Fred MAO,Partner&Managing Director,Frost & Sullivan
Ning YUAN,Deputy Chief Business Officer,Fosun Pharma
Andy Fu, PharmD, MBA,Co-Founder, Chief Business Officer,OnCusp Therapeutics 
Dr.Marietta WU,Managing Director,Quan Capital
Jason Li,CFO,RemeGen Ltd.
 
活动免费，名额有限。扫码报名，先到先得！
 
联系人CONTACT：李女士 Miss Li
电话TEL：18317040595
邮件EMAIL：1583832312@qq.com